Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors

[1]  G. Bosl,et al.  Development of a risk stratification system to guide treatment for female germ cell tumors. , 2015, Gynecologic oncology.

[2]  D. Matei,et al.  High-dose chemotherapy for recurrent ovarian germ cell tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Pedrazzoli,et al.  High-dose chemotherapy for germ cell tumors: do we have a model? , 2015, Expert opinion on biological therapy.

[4]  R. Motzer,et al.  High-dose chemotherapy and stem cell transplantation for advanced testicular cancer , 2011, Expert review of anticancer therapy.

[5]  Andrew Kramar,et al.  Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Bains,et al.  TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Motzer,et al.  Medical treatment of advanced testicular cancer. , 2008, JAMA.

[8]  S. Perkins,et al.  High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. , 2007, The New England journal of medicine.

[9]  C. Bokemeyer,et al.  Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Motzer,et al.  Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Bains,et al.  Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Dini,et al.  Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours , 2005, British Journal of Cancer.

[13]  W. Siegert,et al.  A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  S. Fosså,et al.  Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Richard Sylvester,et al.  International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .

[16]  P. Wilkinson,et al.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.